77%).Data on OS are immature and not significant (HR, 0.70; 95% CI, 0.47–1.05).Patients receiving T-DM1 were more likely to discontinue treatment because of an adverse event (18% vs.
2.1%) and had a higher frequency of sensory neuropathy (18.6% vs.
6.9%), most cases of which had resolved at the time of the analysis.On subgroup analysis, the benefit of T-DM1 was observed in all subgroups, including participants who received dual HER2-targeted therapy in the preoperative setting.
At the time of a planned interim analysis, IDFS was significantly higher in the T-DM1 group than in the trastuzumab group (HRinvasive disease or death, 0.50; 95% CI, 0.39–0.64;P< .001; IDFS at 3 years, 88.3% vs.